Protalix BioTherapeutics Inc (PLX)

[midastouch017]

American Stock Exchange Lists Common Stock of Protalix BioTherapeutics, Inc.
Monday March 12, 12:21 pm ET

NEW YORK, March 12 /PRNewswire/ -- The American Stock Exchange® (Amex®) today listed the common stock of Protalix BioTherapeutics, Inc. under the ticker symbol PLX.
The Company is an emerging clinical stage biopharmaceutical company that is focused on developing and producing recombinant therapeutic proteins that are produced through a proprietary plant cell system.

"We are very pleased to welcome Protalix BioTherapeutics, Inc. to the American Stock Exchange," said John McGonegal, Senior Vice President of the Amex Equities Group. "In listing at the Amex, we will be able to offer Protalix the value-added services that a growing company needs to succeed in today's competitive market."

Yossi Maimon, Chief Financial Officer of Protalix BioTherapeutics, Inc. said, "We are excited about our listing on the American Stock Exchange. We view this as a milestone event in our Company's evolution. We believe that this listing will be of significant benefit to us and to our shareholders as we continue to expand our business platform."

The specialist in Protalix BioTherapeutics, Inc. will be Weiskopf Silver & Co. For further information on PLX and other Amex-listed companies, please visit www.amex.com.

http://biz.yahoo.com/prnews/070312/clm510.html?.v=65